June 15, 2017 / 11:33 AM / 2 years ago

BRIEF-Applied Genetic Technologies updates on clinical development of AGTC-402

June 15 (Reuters) - Applied Genetic Technologies Corp :

* Enabling study data published in human gene therapy clinical development support clinical development of AGTC-402 for the treatment of CNGA3-deficient achromatopsia

* ‍Subretinal injections were generally well tolerated and were not associated with any systemic toxicity​

* ‍No serum antibodies against human CNGA3 protein were detected in any vector-treated animal​

* ‍Most animals had mild to moderate side effects thought to be related to surgical procedure

* ‍Mild to moderate side effects generally resolved without further intervention​

* ‍Currently scheduling patients for enrollment in Phase I/II trial in patient population

* continue enrollment in clinical trial for patients with CNGB3 achromatopsia​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below